The U.S. Supreme Court unanimously sided with Hikma in a “skinny label” patent case involving Hikma’s generic version of Amarin’s Vascepa. The ruling held Hikma’s product did not infringe on Amarin’s patents, overturning a lower-court decision and reinforcing the legal framework for generic marketing tied to specific indications. The decision has direct implications for availability of less expensive versions of Vascepa and for how generic makers structure labeling and marketing to avoid infringement. Amarin reported $214 million in Vascepa sales last year.